LAVAL, QC, Feb. 6, 2017 /CNW Telbec/ - ProMetic Life
Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") announced today that California Capital Equity,
LLC, has exercised 44,791,488 share purchase warrants at a price of $0.47 per share for total
proceeds of $21,051,999.36 to the Corporation.
"Our increased equity position in ProMetic represents a long term and strategic investment for us", said Dr. Patrick Soon-Shiong, Chief Executive Officer of California Capital Equity, LLC. "ProMetic has robust
proprietary therapeutic platforms, promising growth potential and several plasma derived therapeutics expected to reach
commercialization stages, starting in 2017 with plasminogen. We, through other investment vehicles, also have an on-going
partnership with ProMetic in relation to IVIG and anticipate further collaborations going forward", added Dr. Soon-Shiong.
Commenting on the exercise of warrants by California Capital Equity, LLC., Mr. Pierre Laurin,
President and Chief Executive Officer of ProMetic Life Sciences Inc., said: "We are delighted to see our long-standing
relationship with Dr. Soon-Shiong, which dates back to 2008, continue to evolve as we prepare for our first commercial launch in
2017".
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (www.prometic.com) is a long
established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and
small-molecule drug development. ProMetic offers its state of the art technologies for large-scale purification of
biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own
affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in
order to develop best-in-class therapeutics and orphan drugs. ProMetic is also active in developing its own novel small-molecule
therapeutic products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer and autoimmune
diseases/inflammation as well as certain nephropathies. Headquartered in Laval (Canada), ProMetic
has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and commercial activities in the U.S.,
Canada, Europe, Russia, Asia
and Australia.
Forward Looking Statements
This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve
risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the
markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those
anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions
turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop,
manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to
pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of
business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in
economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to
materially differ from our current expectations in ProMetic's Annual Information Form for the year ended December 31, 2015, under the heading "Risk and Uncertainties related to ProMetic's business". As a
result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any
forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless
required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.
SOURCE ProMetic Life Sciences Inc.
To view this news release in HTML formatting, please use the following URL:
http://www.newswire.ca/en/releases/archive/February2017/06/c3576.html